U.S. markets closed
  • S&P 500

    4,071.70
    -4.87 (-0.12%)
     
  • Dow 30

    34,429.88
    +34.87 (+0.10%)
     
  • Nasdaq

    11,461.50
    -20.95 (-0.18%)
     
  • Russell 2000

    1,892.84
    +11.16 (+0.59%)
     
  • Crude Oil

    80.34
    -0.88 (-1.08%)
     
  • Gold

    1,797.30
    -3.80 (-0.21%)
     
  • Silver

    23.35
    +0.51 (+2.25%)
     
  • EUR/USD

    1.0531
    +0.0002 (+0.02%)
     
  • 10-Yr Bond

    3.5060
    -0.0230 (-0.65%)
     
  • GBP/USD

    1.2296
    +0.0040 (+0.33%)
     
  • USD/JPY

    134.2710
    -1.0350 (-0.76%)
     
  • BTC-USD

    17,041.84
    +44.42 (+0.26%)
     
  • CMC Crypto 200

    404.33
    +2.91 (+0.72%)
     
  • FTSE 100

    7,556.23
    -2.26 (-0.03%)
     
  • Nikkei 225

    27,777.90
    -448.18 (-1.59%)
     

Medical Properties (MPW) Stock Moves -1.22%: What You Should Know

Medical Properties (MPW) closed at $12.98 in the latest trading session, marking a -1.22% move from the prior day. This change was narrower than the S&P 500's daily loss of 1.71%. Elsewhere, the Dow lost 1.7%, while the tech-heavy Nasdaq lost 0.07%.

Coming into today, shares of the health care real estate investment trust had lost 12.63% in the past month. In that same time, the Finance sector lost 6.28%, while the S&P 500 lost 8.68%.

Wall Street will be looking for positivity from Medical Properties as it approaches its next earnings report date. On that day, Medical Properties is projected to report earnings of $0.45 per share, which would represent year-over-year growth of 2.27%. Our most recent consensus estimate is calling for quarterly revenue of $391.44 million, up 0.17% from the year-ago period.

For the full year, our Zacks Consensus Estimates are projecting earnings of $1.82 per share and revenue of $1.59 billion, which would represent changes of +4% and +3.02%, respectively, from the prior year.

Investors might also notice recent changes to analyst estimates for Medical Properties. These recent revisions tend to reflect the evolving nature of short-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.

Research indicates that these estimate revisions are directly correlated with near-term share price momentum. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.

The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.18% higher. Medical Properties currently has a Zacks Rank of #3 (Hold).

Investors should also note Medical Properties's current valuation metrics, including its Forward P/E ratio of 7.23. This represents a discount compared to its industry's average Forward P/E of 12.45.

Also, we should mention that MPW has a PEG ratio of 0.72. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. REIT and Equity Trust - Other stocks are, on average, holding a PEG ratio of 2.08 based on yesterday's closing prices.

The REIT and Equity Trust - Other industry is part of the Finance sector. This group has a Zacks Industry Rank of 70, putting it in the top 28% of all 250+ industries.

The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

To follow MPW in the coming trading sessions, be sure to utilize Zacks.com.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Medical Properties Trust, Inc. (MPW) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research